Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib.

In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.
Competing Interests: Declaration of interests W.L.K. is a founder for Ribon Therapeutics, Inc.; a founder, consultant, and SAB member for ARase Therapeutics, Inc.; and a consultant and SAB member for Alphina Therapeutics, Inc. He is also a co-holder of U.S. Patent 9,599,606 covering a set of ADP-ribose detection reagents, which have been licensed to and are sold by EMD Millipore.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)